Patterns of Prophylactic Anticoagulation Among Patients Hospitalized for COVID‐19: An Analysis of the American Heart Association COVID‐19 Cardiovascular Disease Registry
Background Limited knowledge exists about prophylactic anticoagulation patterns in patients hospitalized for COVID‐19. Methods and Results We conducted a retrospective cohort study using American Heart Association COVID‐19 Cardiovascular Disease Registry data from May 2020 to March 2022. We included...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-03-01
|
| Series: | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease |
| Subjects: | |
| Online Access: | https://www.ahajournals.org/doi/10.1161/JAHA.123.034186 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850201153680179200 |
|---|---|
| author | Mathew S. Lopes Hsin‐Fang Li Reed J. D. Sorensen Sandeep Das Steven M. Bradley James A. de Lemos Gregory A. Roth Tracy Wang Erin A. Bohula Ty J. Gluckman |
| author_facet | Mathew S. Lopes Hsin‐Fang Li Reed J. D. Sorensen Sandeep Das Steven M. Bradley James A. de Lemos Gregory A. Roth Tracy Wang Erin A. Bohula Ty J. Gluckman |
| author_sort | Mathew S. Lopes |
| collection | DOAJ |
| description | Background Limited knowledge exists about prophylactic anticoagulation patterns in patients hospitalized for COVID‐19. Methods and Results We conducted a retrospective cohort study using American Heart Association COVID‐19 Cardiovascular Disease Registry data from May 2020 to March 2022. We included patients without preexisting indications for or contraindications to anticoagulation, excluding those with missing anticoagulation data. Patients were categorized by the highest anticoagulation dose received. Multilevel logistic regression was used to assess the relationship between anticoagulation use/dose, patient demographics, clinical presentation, in‐hospital course, institutional characteristics, and admission date, accounting for hospital clustering. Among 26 775 patients, 4157 (16%) received no anticoagulation, 15 617 (58%) low‐dose, 3071 (11%) intermediate‐dose, and 3930 (15%) full‐dose anticoagulation. Significant hospital‐level variability occurred for any anticoagulation use (range, 0%–98%; P<0.0001) and by dose (full anticoagulation range, 0%–85%; P<0.0001). Controlling for hospital variability, older age, male sex, non‐White race, higher body mass index, higher platelets, corticosteroid use, and intensive care unit admission were positively associated with any anticoagulation use. Older age, male sex, higher body mass index, higher platelets, corticosteroid use, intensive care unit admission, mechanical ventilation, and admission before October 2020 were associated with higher anticoagulation dose (full versus low dose). Rates of no anticoagulation significantly increased in both intensive care unit and non‐intensive care unit strata over time (P trend=0.01 and <0.0001, respectively). Conclusions In this large real‐world analysis, nearly 1 in 6 patients hospitalized for COVID‐19 received no prophylactic anticoagulation. Patient and disease characteristics associated with thrombotic risk and COVID‐19 severity correlated with anticoagulation strategy. Importantly, substantial institutional differences emerged, highlighting gaps between clinical practice and guideline recommendations. |
| format | Article |
| id | doaj-art-45eaec2577bb40c2902229bdab612ead |
| institution | OA Journals |
| issn | 2047-9980 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease |
| spelling | doaj-art-45eaec2577bb40c2902229bdab612ead2025-08-20T02:12:06ZengWileyJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease2047-99802025-03-0114510.1161/JAHA.123.034186Patterns of Prophylactic Anticoagulation Among Patients Hospitalized for COVID‐19: An Analysis of the American Heart Association COVID‐19 Cardiovascular Disease RegistryMathew S. Lopes0Hsin‐Fang Li1Reed J. D. Sorensen2Sandeep Das3Steven M. Bradley4James A. de Lemos5Gregory A. Roth6Tracy Wang7Erin A. Bohula8Ty J. Gluckman9Division of Cardiovascular Medicine Brigham and Women’s Hospital Boston MA USACenter for Cardiovascular Analytics, Research, and Data Science (CARDS) Providence Heart Institute Portland OR USAInstitute for Health Metrics and Evaluation, University of Washington Seattle WA USAUT Southwestern Medical Center Dallas TX USAMinneapolis Heart Institute Minneapolis MN USAUT Southwestern Medical Center Dallas TX USADivision of Cardiology, Department of Medicine University of Washington Seattle WA USADuke Clinical Research Institute Durham NC USADivision of Cardiovascular Medicine Brigham and Women’s Hospital Boston MA USACenter for Cardiovascular Analytics, Research, and Data Science (CARDS) Providence Heart Institute Portland OR USABackground Limited knowledge exists about prophylactic anticoagulation patterns in patients hospitalized for COVID‐19. Methods and Results We conducted a retrospective cohort study using American Heart Association COVID‐19 Cardiovascular Disease Registry data from May 2020 to March 2022. We included patients without preexisting indications for or contraindications to anticoagulation, excluding those with missing anticoagulation data. Patients were categorized by the highest anticoagulation dose received. Multilevel logistic regression was used to assess the relationship between anticoagulation use/dose, patient demographics, clinical presentation, in‐hospital course, institutional characteristics, and admission date, accounting for hospital clustering. Among 26 775 patients, 4157 (16%) received no anticoagulation, 15 617 (58%) low‐dose, 3071 (11%) intermediate‐dose, and 3930 (15%) full‐dose anticoagulation. Significant hospital‐level variability occurred for any anticoagulation use (range, 0%–98%; P<0.0001) and by dose (full anticoagulation range, 0%–85%; P<0.0001). Controlling for hospital variability, older age, male sex, non‐White race, higher body mass index, higher platelets, corticosteroid use, and intensive care unit admission were positively associated with any anticoagulation use. Older age, male sex, higher body mass index, higher platelets, corticosteroid use, intensive care unit admission, mechanical ventilation, and admission before October 2020 were associated with higher anticoagulation dose (full versus low dose). Rates of no anticoagulation significantly increased in both intensive care unit and non‐intensive care unit strata over time (P trend=0.01 and <0.0001, respectively). Conclusions In this large real‐world analysis, nearly 1 in 6 patients hospitalized for COVID‐19 received no prophylactic anticoagulation. Patient and disease characteristics associated with thrombotic risk and COVID‐19 severity correlated with anticoagulation strategy. Importantly, substantial institutional differences emerged, highlighting gaps between clinical practice and guideline recommendations.https://www.ahajournals.org/doi/10.1161/JAHA.123.034186anticoagulationCOVID‐19prophylaxisregistrySARS‐CoV‐2 |
| spellingShingle | Mathew S. Lopes Hsin‐Fang Li Reed J. D. Sorensen Sandeep Das Steven M. Bradley James A. de Lemos Gregory A. Roth Tracy Wang Erin A. Bohula Ty J. Gluckman Patterns of Prophylactic Anticoagulation Among Patients Hospitalized for COVID‐19: An Analysis of the American Heart Association COVID‐19 Cardiovascular Disease Registry Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease anticoagulation COVID‐19 prophylaxis registry SARS‐CoV‐2 |
| title | Patterns of Prophylactic Anticoagulation Among Patients Hospitalized for COVID‐19: An Analysis of the American Heart Association COVID‐19 Cardiovascular Disease Registry |
| title_full | Patterns of Prophylactic Anticoagulation Among Patients Hospitalized for COVID‐19: An Analysis of the American Heart Association COVID‐19 Cardiovascular Disease Registry |
| title_fullStr | Patterns of Prophylactic Anticoagulation Among Patients Hospitalized for COVID‐19: An Analysis of the American Heart Association COVID‐19 Cardiovascular Disease Registry |
| title_full_unstemmed | Patterns of Prophylactic Anticoagulation Among Patients Hospitalized for COVID‐19: An Analysis of the American Heart Association COVID‐19 Cardiovascular Disease Registry |
| title_short | Patterns of Prophylactic Anticoagulation Among Patients Hospitalized for COVID‐19: An Analysis of the American Heart Association COVID‐19 Cardiovascular Disease Registry |
| title_sort | patterns of prophylactic anticoagulation among patients hospitalized for covid 19 an analysis of the american heart association covid 19 cardiovascular disease registry |
| topic | anticoagulation COVID‐19 prophylaxis registry SARS‐CoV‐2 |
| url | https://www.ahajournals.org/doi/10.1161/JAHA.123.034186 |
| work_keys_str_mv | AT mathewslopes patternsofprophylacticanticoagulationamongpatientshospitalizedforcovid19ananalysisoftheamericanheartassociationcovid19cardiovasculardiseaseregistry AT hsinfangli patternsofprophylacticanticoagulationamongpatientshospitalizedforcovid19ananalysisoftheamericanheartassociationcovid19cardiovasculardiseaseregistry AT reedjdsorensen patternsofprophylacticanticoagulationamongpatientshospitalizedforcovid19ananalysisoftheamericanheartassociationcovid19cardiovasculardiseaseregistry AT sandeepdas patternsofprophylacticanticoagulationamongpatientshospitalizedforcovid19ananalysisoftheamericanheartassociationcovid19cardiovasculardiseaseregistry AT stevenmbradley patternsofprophylacticanticoagulationamongpatientshospitalizedforcovid19ananalysisoftheamericanheartassociationcovid19cardiovasculardiseaseregistry AT jamesadelemos patternsofprophylacticanticoagulationamongpatientshospitalizedforcovid19ananalysisoftheamericanheartassociationcovid19cardiovasculardiseaseregistry AT gregoryaroth patternsofprophylacticanticoagulationamongpatientshospitalizedforcovid19ananalysisoftheamericanheartassociationcovid19cardiovasculardiseaseregistry AT tracywang patternsofprophylacticanticoagulationamongpatientshospitalizedforcovid19ananalysisoftheamericanheartassociationcovid19cardiovasculardiseaseregistry AT erinabohula patternsofprophylacticanticoagulationamongpatientshospitalizedforcovid19ananalysisoftheamericanheartassociationcovid19cardiovasculardiseaseregistry AT tyjgluckman patternsofprophylacticanticoagulationamongpatientshospitalizedforcovid19ananalysisoftheamericanheartassociationcovid19cardiovasculardiseaseregistry |